Novel biomarkers: the RUNX family as prognostic predictors in colorectal cancer
While biomarkers have been shown to enhance the prognosis of patients with colorectal cancer (CRC) compared to conventional treatments, there is a pressing need to discover novel biomarkers that can assist in assessing the prognostic impact of immunotherapy and in formulating individualized treatmen...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1430136/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841526960534061056 |
|---|---|
| author | Yingting Liu Yingting Liu Yingting Liu Junjun Chen Junjun Chen Junjun Chen An Li An Li An Li Yue Wu Yue Wu Yue Wu Junwei Ge Junwei Ge Junwei Ge Maoling Yuan Maoling Yuan Maoling Yuan Bin Xu Bin Xu Bin Xu Xiao Zheng Xiao Zheng Xiao Zheng Lujun Chen Lujun Chen Lujun Chen Jingting Jiang Jingting Jiang Jingting Jiang |
| author_facet | Yingting Liu Yingting Liu Yingting Liu Junjun Chen Junjun Chen Junjun Chen An Li An Li An Li Yue Wu Yue Wu Yue Wu Junwei Ge Junwei Ge Junwei Ge Maoling Yuan Maoling Yuan Maoling Yuan Bin Xu Bin Xu Bin Xu Xiao Zheng Xiao Zheng Xiao Zheng Lujun Chen Lujun Chen Lujun Chen Jingting Jiang Jingting Jiang Jingting Jiang |
| author_sort | Yingting Liu |
| collection | DOAJ |
| description | While biomarkers have been shown to enhance the prognosis of patients with colorectal cancer (CRC) compared to conventional treatments, there is a pressing need to discover novel biomarkers that can assist in assessing the prognostic impact of immunotherapy and in formulating individualized treatment plans. The RUNX family, consisting of RUNX1, RUNX2, and RUNX3, has been recognized as crucial regulators in developmental processes, with dysregulation of these genes also being implicated in tumorigenesis and cancer progression. In our present study, we demonstrated a crucial regulatory role of RUNX in CD8+T and CD103+CD8+T cell-mediated anti-tumor response within the tumor microenvironment (TME) of human CRC. Specifically, RUNXs were significantly differentially expressed between tumor and normal tissues in CRC. Patients with a greater proportion of infiltrating CD8+RUNX1+, CD103+CD8+RUNX1+, CD8+RUNX2+, CD103+CD8+RUNX2+, CD8+RUNX3+, or CD103+CD8+RUNX3+ T cells demonstrated improved outcomes compared to those with lower proportions. Additionally, the proportions of infiltrating CD8+RUNX1+T and CD8+RUNX3+T cells may serve as valuable prognostic predictors for CRC patients, independent of other clinicopathological factors. Moreover, further bioinformatic analysis conducted utilizing the TISIDB and TIMER platforms demonstrated significant associations between the members of the RUNX family and immune-infiltrating cells, specifically diverse subpopulations of CD8+TILs. Our study of human colorectal cancer tissue microarray (TMA) also revealed positive and statistically significant correlations between the expressions of RUNX1, RUNX2, and RUNX3 in both CD8+T cells and CD103+CD8+T cells. Our study comprehensively revealed the varied expressions and prognostic importance of the RUNX family in human colorectal cancer tissues. It underscored their potential as vital biomarkers for prognostic evaluation in colorectal cancer patients and as promising targets for immunotherapy in treating this disease. |
| format | Article |
| id | doaj-art-7812dd1357464d1a8dc1bfd3cf9567b1 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-7812dd1357464d1a8dc1bfd3cf9567b12025-01-16T09:35:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-12-011510.3389/fimmu.2024.14301361430136Novel biomarkers: the RUNX family as prognostic predictors in colorectal cancerYingting Liu0Yingting Liu1Yingting Liu2Junjun Chen3Junjun Chen4Junjun Chen5An Li6An Li7An Li8Yue Wu9Yue Wu10Yue Wu11Junwei Ge12Junwei Ge13Junwei Ge14Maoling Yuan15Maoling Yuan16Maoling Yuan17Bin Xu18Bin Xu19Bin Xu20Xiao Zheng21Xiao Zheng22Xiao Zheng23Lujun Chen24Lujun Chen25Lujun Chen26Jingting Jiang27Jingting Jiang28Jingting Jiang29Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaJiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, ChinaInstitute of Cell Therapy, Soochow University, Changzhou, Jiangsu, ChinaDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaJiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, ChinaInstitute of Cell Therapy, Soochow University, Changzhou, Jiangsu, ChinaDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaJiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, ChinaInstitute of Cell Therapy, Soochow University, Changzhou, Jiangsu, ChinaDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaJiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, ChinaInstitute of Cell Therapy, Soochow University, Changzhou, Jiangsu, ChinaDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaJiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, ChinaInstitute of Cell Therapy, Soochow University, Changzhou, Jiangsu, ChinaDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaJiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, ChinaInstitute of Cell Therapy, Soochow University, Changzhou, Jiangsu, ChinaDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaJiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, ChinaInstitute of Cell Therapy, Soochow University, Changzhou, Jiangsu, ChinaDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaJiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, ChinaInstitute of Cell Therapy, Soochow University, Changzhou, Jiangsu, ChinaDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaJiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, ChinaInstitute of Cell Therapy, Soochow University, Changzhou, Jiangsu, ChinaDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaJiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, ChinaInstitute of Cell Therapy, Soochow University, Changzhou, Jiangsu, ChinaWhile biomarkers have been shown to enhance the prognosis of patients with colorectal cancer (CRC) compared to conventional treatments, there is a pressing need to discover novel biomarkers that can assist in assessing the prognostic impact of immunotherapy and in formulating individualized treatment plans. The RUNX family, consisting of RUNX1, RUNX2, and RUNX3, has been recognized as crucial regulators in developmental processes, with dysregulation of these genes also being implicated in tumorigenesis and cancer progression. In our present study, we demonstrated a crucial regulatory role of RUNX in CD8+T and CD103+CD8+T cell-mediated anti-tumor response within the tumor microenvironment (TME) of human CRC. Specifically, RUNXs were significantly differentially expressed between tumor and normal tissues in CRC. Patients with a greater proportion of infiltrating CD8+RUNX1+, CD103+CD8+RUNX1+, CD8+RUNX2+, CD103+CD8+RUNX2+, CD8+RUNX3+, or CD103+CD8+RUNX3+ T cells demonstrated improved outcomes compared to those with lower proportions. Additionally, the proportions of infiltrating CD8+RUNX1+T and CD8+RUNX3+T cells may serve as valuable prognostic predictors for CRC patients, independent of other clinicopathological factors. Moreover, further bioinformatic analysis conducted utilizing the TISIDB and TIMER platforms demonstrated significant associations between the members of the RUNX family and immune-infiltrating cells, specifically diverse subpopulations of CD8+TILs. Our study of human colorectal cancer tissue microarray (TMA) also revealed positive and statistically significant correlations between the expressions of RUNX1, RUNX2, and RUNX3 in both CD8+T cells and CD103+CD8+T cells. Our study comprehensively revealed the varied expressions and prognostic importance of the RUNX family in human colorectal cancer tissues. It underscored their potential as vital biomarkers for prognostic evaluation in colorectal cancer patients and as promising targets for immunotherapy in treating this disease.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1430136/fullRUNXtumor-infiltrating CD8+T cellsmulti-color immunohistochemical stainingcolorectal cancerprognosis |
| spellingShingle | Yingting Liu Yingting Liu Yingting Liu Junjun Chen Junjun Chen Junjun Chen An Li An Li An Li Yue Wu Yue Wu Yue Wu Junwei Ge Junwei Ge Junwei Ge Maoling Yuan Maoling Yuan Maoling Yuan Bin Xu Bin Xu Bin Xu Xiao Zheng Xiao Zheng Xiao Zheng Lujun Chen Lujun Chen Lujun Chen Jingting Jiang Jingting Jiang Jingting Jiang Novel biomarkers: the RUNX family as prognostic predictors in colorectal cancer Frontiers in Immunology RUNX tumor-infiltrating CD8+T cells multi-color immunohistochemical staining colorectal cancer prognosis |
| title | Novel biomarkers: the RUNX family as prognostic predictors in colorectal cancer |
| title_full | Novel biomarkers: the RUNX family as prognostic predictors in colorectal cancer |
| title_fullStr | Novel biomarkers: the RUNX family as prognostic predictors in colorectal cancer |
| title_full_unstemmed | Novel biomarkers: the RUNX family as prognostic predictors in colorectal cancer |
| title_short | Novel biomarkers: the RUNX family as prognostic predictors in colorectal cancer |
| title_sort | novel biomarkers the runx family as prognostic predictors in colorectal cancer |
| topic | RUNX tumor-infiltrating CD8+T cells multi-color immunohistochemical staining colorectal cancer prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1430136/full |
| work_keys_str_mv | AT yingtingliu novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT yingtingliu novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT yingtingliu novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT junjunchen novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT junjunchen novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT junjunchen novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT anli novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT anli novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT anli novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT yuewu novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT yuewu novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT yuewu novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT junweige novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT junweige novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT junweige novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT maolingyuan novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT maolingyuan novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT maolingyuan novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT binxu novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT binxu novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT binxu novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT xiaozheng novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT xiaozheng novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT xiaozheng novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT lujunchen novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT lujunchen novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT lujunchen novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT jingtingjiang novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT jingtingjiang novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer AT jingtingjiang novelbiomarkerstherunxfamilyasprognosticpredictorsincolorectalcancer |